Using the IHC method, the authors of a number of earlier studies have demonstrated that COX‐2 is frequently expressed in a variety of human cancers, including lung cancer 30, breast carcinoma 20, colorectal cancer 63, and nasopharyngeal carcinoma 64. Here, PTGS2 is linked to nasopharyngeal carcinoma.